Medical Oncology

Gastroenterology

Questions discussed in this category

How do you counsel patients on semaglutide or tirzepatide in light of potential cancer risks?

Do you avoid using these agents only in patients with history of medullary thyroid cancer or pancreatic cancer? Are there other cancer risks we should...

1 Answer available

Would you offer chemoRT to a colon cancer case with a resected polyp with positive margins if the patient wishes to avoid surgery?

Would chemoRT be preferred over surgery if there is LVI or PNI?

3 Answers available

What non-variceal EGD findings, if any, deter you from using atezo/bev in patients with advanced HCC?

Would portal hypertensive gastropathy or colopathy sway you away from using it?

2 Answers available

How long should surgery be delayed in a patient with localized, resectable pancreatic cancer who developed acute pancreatitis following EUS guided biopsy?

And if delayed, should chemotherapy be started?

2 Answers available

How would you manage a solitary unresectable liver metastasis?

From NCCN (Rectal MS-33): SBRT is a reasonable option for patients who cannot be resected or ablated. What is the role of SBRT versus microwave ablat...

2 Answers available

What is your approach to working up diarrhea in an immunocompromised patient?

1 Answer available

In a patient with recurrent fibrolamellar HCC a year after upfront resection (previously refused adjuvant therapy) with a solitary abdominal mass, would you offer neoadjuvant therapy to assess response?

Or offer resection followed by adjuvant therapy?

2 Answers available

Would you treat an unresectable MSI-H colon cancer patient with persistent hepatitis C with immunotherapy?

1 Answer available

How do you counsel cancer patients when they ask if they should avoid sugar?

9 Answers available

How do you manage patients with suspected cholangiocarcinoma that presents with biliary obstruction but has repeated negative brushings/biopsies?

Is liquid biopsy helpful? Would you treat if this shows somatic mutation?

2 Answers available

How do you employ focal therapies in localized hepatocellular carcinoma?

Will the results of the recently published randomized comparison of proton beam therapy (PBT) vs. transarterial chemoembolization (TACE) change the wa...

2 Answers available

How would you treat a patient with metastatic cancer with a lesion invading the small bowel causing bleeding and potential obstruction?

Is radiation effective in this case and if so, what dose would you use? Is there potential for perforation?

2 Answers available

How would you treat a patient with recurrent metastatic HCC 6 years after liver transplant for HCC?

1 Answer available

How do you select systemic therapy for advanced HCC patients with portal vein thrombosis?

2 Answers available

What is your treatment approach for a patient with metastatic hepatocellular carcinoma with Child's Pugh B cirrhosis?

How do you sequence systemic treatment options for in patients with Child's Pugh B (or greater) in context of IMbrave150 and HIMALAYA? When do you in...

4 Answers available

How would you approach a patient with imaging and labs suggestive of potentially resectable cholangiocarcinoma when several core biopsies reveal bridging fibrosis with no malignant cells?

1 Answer available

In patients with HCC and asymptomatic but endoscopically visible varices, how long do you wait to start bevacizumab after banding?

1 Answer available

Is there a role for liver transplantation in an initially unresectable HCC with a complete response after bevacizumab-atezolizumab?

1 Answer available

What is the role of liver transplant in NET?

3 Answers available

Would you recommend stent placement upfront in a patient with cervical esophageal cancer and a TE fistula?

2 Answers available

Would you recommend aspirin 600 mg daily for two years to a patient with Lynch syndrome and a history of colon cancer based on the results of the CAPP2 study for cancer prevention?

Would you offer low dose or standard dose aspirin instead?

1 Answer available

Do you routinely start anticoagulation for a patient with newly diagnosed hepatocellular carcinoma presenting with a portal venous thrombosis?

3 Answers available

What is your preferred second line therapy for an HCC patient who progressed after first line checkpoint inhibitor monotherapy?

Would you try atezolizumab/bevacizumab or switch to a TKI?

2 Answers available

Is anticoagulation a relative contraindication to atezolizumab/bevacizumab for advanced HCC?

For example in a patient with a history of PE?

3 Answers available

For patients with HCC receiving atezo/bev, would you advise any other clinical investigations scheduled during treatment other than basic lab monitoring?

i.e. EGD surveillance for varices?

3 Answers available

Are there any biomarkers that might indicate who might be responders to atezolizumab/bevacizumab for HCC?

ex. VEGFR2 expression, inflammatory signature, PDL1, etc.

2 Answers available

How do you manage patients on atezolizumab/bevacizumab with advanced HCC who develop arterial thrombosis?

Do you continue atezolizumab alone? Would you avoid anticoagulation?

6 Answers available

For patients with HCC that have stable disease on immunotherapy alone, would you consider adding bevacizumab at the time of disease progression and continue immunotherapy?

2 Answers available

How do you decide between systemic vs. arterially directed therapies in the first line setting for unresectable HCC?

In light of the SIRveNIB trial results and now IMbrave150, what is the role of intra-arterial therapy now?

2 Answers available

Would you use upfront atezo/bev in a patient with HCC and untreated hepatitis?

3 Answers available

Do you refer all of your patients for EGD prior to initiation of atezolizumab/bevacizumab for advanced HCC?

Do you screen even asymptomatic patients?

4 Answers available

Are you routinely using thrombopoietin agonists in patients with hep C and HCC?

If so, for what platelet count threshold and do you have a preference as to which agent?

1 Answer available

How do you sequence antiviral therapy and cancer-directed therapy in a newly diagnosed patient with hepatocellular carcinoma and incidentally found hepatitis C?

Is there a "best" way to approach treatment of the viral infection i.e concurrently with therapy, prior to therapy, delayed or post therapy? Does this...

1 Answer available

How do you manage venous thromboembolic events or bleeding events in RCC or HCC patients on anti-angiogenic TKIs?

Arterial events have clear instructions to permanently discontinue on the FDA label. Especially in HCC without many other treatment options, giv...

1 Answer available

Are you categorically using lenvatinib over sorafenib for unresectable HCC in the absence of contraindications?

3 Answers available

Is it necessary to hold immunotherapy during a 4-6wk steroid taper after resolution of immunotherapy related toxicity?

Would you ever considering re-starting immunotherapy before completing the taper? According to the new guildelines on managing immunotherapy related ...

1 Answer available

Would you recommend sorafenib as an adjunct to liver targeted therapy in patients with hepatocellular carcinoma who are awaiting liver transplant?

1 Answer available

Could a non-cirrhotic patient with a single HCC lesion measuring >5cm who is ineligible for liver transplant by Milan size criteria alone become a candidate if the tumor shrinks after TACE?

1 Answer available

When do you perform HER2 testing in patients with colorectal cancer?

1 Answer available

When do you perform BRAF testing in colon cancer?

1 Answer available